The global allogeneic cell therapy market size was estimated at USD 255.6 million in 2022 and is projected to reach USD 1.72 billion by 2030, growing at a CAGR of 27.4% from 2023 to 2030. This rapid growth reflects the increasing recognition of allogeneic cell therapy as a promising treatment approach for a wide range of chronic and life-threatening diseases. The rising incidence of chronic conditions such as cancer, cardiovascular diseases, autoimmune disorders, and genetic diseases is a major factor driving market expansion. According to the American Cancer Society, approximately 1.9 million new cancer cases were diagnosed in the U.S. in 2022 alone, resulting in over 609,000 deaths, underscoring the urgent need for more effective and scalable treatment options. In addition, the global aging population is expected to further increase the prevalence of chronic illnesses, as older individuals are more susceptible to long-term and degenerative diseases. Collectively, these trends highlight the growing demand for advanced therapeutic solutions such as allogeneic cell therapy, which offers the potential for improved patient outcomes, reduced treatment timelines, and broader accessibility compared to conventional therapies.

Moreover, there has been a notable shift in the focus of clinical research from autologous to allogeneic cell therapy, as developers seek solutions that are more scalable and cost-effective. A growing number of pharmaceutical and biotechnology companies are conducting clinical trials for allogeneic cell therapy candidates targeting various indications, including cancer, genetic disorders, and autoimmune diseases. This shift is driven by the advantages of allogeneic therapies, such as off-the-shelf availability, standardized manufacturing, and reduced treatment delays. The trend is expected to continue as governments, private organizations, and biotechnology firms increasingly prioritize investments in the development and commercialization of allogeneic cell therapies. Supportive regulatory frameworks and collaborative research initiatives are further accelerating progress in this field.

Furthermore, the allogeneic cell therapy industry is anticipated to grow significantly due to rising investments in research and development by both public and private entities. Governments and research institutions are actively funding innovative approaches aimed at improving the safety, efficacy, and scalability of allogeneic therapies. For example, in November 2022, the California Institute for Regenerative Medicine (CIRM) Board awarded more than USD 6 million to Jianhua Yu at the Beckman Research Institute of City of Hope to develop a novel strategy for targeting hypoxia-associated metastatic breast tumors using allogeneic off-the-shelf anti-EGFR CAR NK cells. This research initiative aims to enhance the therapeutic effectiveness and safety profile of cancer treatments, demonstrating the strong institutional support for advancing next-generation allogeneic cell therapies.

Key Market Trends & Insights:

• North America accounted for the largest share of the allogeneic cell therapy market in 2022, capturing 80.42% of total revenue. This dominance is attributed to the region’s well-established healthcare infrastructure, strong presence of leading biotechnology companies, and the high prevalence of chronic diseases that require advanced therapeutic interventions.
• Europe is expected to witness a significant growth rate in the allogeneic cell therapy market from 2023 to 2030. Factors contributing to this growth include increasing investments in regenerative medicine research, favorable government policies, and rising awareness of advanced cell-based therapies across the region.
• By therapeutic area, the hematological disorders segment dominated the market, accounting for 58.22% of the total share in 2022. This leadership is driven by the extensive use of allogeneic cell therapies in treating blood-related cancers and disorders. In contrast, the dermatological disorders segment is expected to register a rapid CAGR by 2030, supported by a growing pipeline of cell-based therapies under development for skin-related conditions.
• By therapy type, the stem cell therapies segment held the largest market share at 77% in 2022, reflecting their widespread application and established clinical utility. Meanwhile, the non-stem cell therapies segment is projected to grow at the fastest CAGR of 31.32% by 2030, driven by the rapid expansion of CAR-T therapy clinical trials and their comparatively higher success rates in targeted disease treatment.

Order a free sample PDF of the Allogeneic Cell Therapy Market Intelligence Study, published by Grand View Research.

Market Size & Forecast:

• 2022 Market Size: USD 255.6 Million
• 2030 Projected Market Size: USD 1.72 Billion
• CAGR (2023-2030): 27.4%
• North America: Largest market in 2022

Key Players

• SSM Cardinal Glennon Children's Medical Center
• Cleveland Cord Blood Center
• Duke University School of Medicine
• New York Blood Center
• Clinimmune Labs, University of Colorado Cord Blood Bank
• MD Anderson Cord Blood Bank
• LifeSouth Community Blood Centers, Inc.
• Bloodworks Northwest
• JCR Pharmaceuticals Co., Ltd.
• Sumitomo Pharma Co., Ltd.
• Atara Biotherapeutics
• Mallinckrodt Pharmaceuticals
• Tego Science Inc
• Takeda Pharmaceutical Company Limited
• STEMPEUTICS RESEARCH PVT LTD
• Biosolution Co., Ltd.
• MEDIPOST Co., Ltd. 

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

In conclusion, the global allogeneic cell therapy market is poised for robust growth, driven by the rising prevalence of chronic and life-threatening diseases such as cancer, autoimmune disorders, and genetic conditions. The increasing global aging population further amplifies the demand for advanced, effective, and scalable therapeutic solutions. A strategic shift in clinical research from autologous to allogeneic therapies is accelerating market momentum, supported by advantages such as off-the-shelf availability and standardized manufacturing. Growing investments from governments, research institutions, and private organizations are strengthening the development pipeline and improving the safety and efficacy of allogeneic treatments. Strong market dominance in North America reflects advanced healthcare infrastructure and high disease prevalence, while Europe is emerging as a high-growth region due to supportive regulatory policies. Additionally, rapid progress in non-stem cell therapies, particularly CAR-T and CAR-NK platforms, is expected to further enhance market expansion. Overall, these combined factors position the allogeneic cell therapy market for sustained and transformative growth over the forecast period.